Check patentability & draft patents in minutes with Patsnap Eureka AI!

Application of DPP-IV inhibitor in type 2 diabetes

A DPP-IV, type 2 diabetes technology, applied in the application field of DPP-IV inhibitors in type 2 diabetes, can solve the problem of poor accuracy and inability to distinguish between equal secretions, and achieve the effect of increasing the concentration and improving insulin secretion

Inactive Publication Date: 2013-11-20
RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

OGTT can assess insulin secretion under glucose load, but because of its poor precision, it cannot distinguish the secretion phase

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of DPP-IV inhibitor in type 2 diabetes
  • Application of DPP-IV inhibitor in type 2 diabetes
  • Application of DPP-IV inhibitor in type 2 diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0027] 1. Researchers: 20 healthy subjects were enrolled, all from the volunteer bank of the Clinical Trial Center of Ruijin Hospital.

[0028] (1) Age: 20-30 years old; gender: male.

[0029] (2)19

[0030] (3) The weight fluctuation within 3 months does not exceed 5%.

[0031] (4) Sign informed consent and have good compliance.

[0032] 2. Test method:

[0033] (1) Test preparation:

[0034] The subjects in the whole test period should consume more than 150g carbohydrates per day and maintain an equal amount of exercise. From 3 days before each test, subjects should avoid taking drugs, stop smoking and drinking, get enough sleep, avoid emotional agitation, and avoid strenuous physical exertion.

[0035] The subjects fasted after 8 o'clock in the evening the day before the test, and took the medicine at 7:00 am on the day of the test after 10-12 hours on an empty stomach. The intravenous oral double high glucose clamp test started at 9:00am that day. (The blank control g...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Relating to the field of medical technologies, the invention in particular relates to application of a DPP-IV inhibitor in type 2 diabetes. The DPP-IV inhibitor is beta phenylethylamine or cyanopyrrolidine. The dosage of the DPP-IV inhibitor is 5-100mg every time, the drug-delivery way is oral administration. In the invention, under intravenous glucose stimulation and combined oral glucose stimulation conditions, the influences of two DPP-IV inhibitors on two-phase insulin secretion functions are compared. By detection, the cyanopyrrolidine DPP-IV inhibitor can remarkably increase the first-phase and second-phase insulin secretion and C peptide secretion, while the beta phenylethylamine DPP-IV inhibitor can obviously increase the first-phase insulin secretion and C peptide secretion. The two DPP-IV inhibitors both can inhibit the secretion of glucagon and increase the concentration of active GLP-1. The invention provides test data for better application of the DPP-IV inhibitor in type 2 diabetes.

Description

Technical field [0001] The invention relates to the technical field of medicine, in particular to the application of a DPP-IV inhibitor in type 2 diabetes. Background technique [0002] Type 2 diabetes has become a global health problem. It is one of the three major killers endangering human health in the 21st century, second only to cardiovascular diseases and tumors. If the patient’s blood sugar is not well controlled, a variety of chronic complications will occur on the basis of arteriosclerosis and microvascular disease, such as diabetic cardio-cerebrovascular disease, diabetic nephropathy, diabetic retinopathy and neuropathy, which will cause great harm and mortality Very high, seriously affecting the quality of life. How to control blood sugar, reduce complications, and improve long-term prognosis is the main goal of diabetes treatment. Since the current methods of treating diabetes still have great limitations, how to effectively control the hyperglycemia of diabetes to ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61K31/403A61K31/4985A61P3/10
Inventor 宁光池洁张翼飞王卫庆
Owner RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com